Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.09), Zacks reports. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. The company had revenue of $3.22 million during the quarter, compared to the consensus estimate of $16.56 million.
Adaptimmune Therapeutics Price Performance
Shares of NASDAQ ADAP traded down $0.01 during midday trading on Friday, hitting $0.21. 2,963,365 shares of the company's stock were exchanged, compared to its average volume of 1,717,621. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. The business's fifty day moving average price is $0.51 and its two-hundred day moving average price is $0.68. The company has a market cap of $52.71 million, a price-to-earnings ratio of -0.94 and a beta of 2.52. Adaptimmune Therapeutics has a 12-month low of $0.20 and a 12-month high of $1.65.
Analyst Ratings Changes
Several brokerages have commented on ADAP. Wells Fargo & Company cut their target price on Adaptimmune Therapeutics from $2.00 to $1.50 and set an "equal weight" rating for the company in a research note on Friday, March 21st. Guggenheim lowered their price target on shares of Adaptimmune Therapeutics from $3.00 to $1.75 and set a "buy" rating on the stock in a report on Wednesday. StockNews.com initiated coverage on shares of Adaptimmune Therapeutics in a research note on Friday, March 21st. They set a "buy" rating for the company. Finally, Scotiabank lowered their target price on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a research note on Friday, March 21st. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Adaptimmune Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $1.93.
Read Our Latest Analysis on ADAP
Adaptimmune Therapeutics Company Profile
(
Get Free Report)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.
Further Reading
Before you consider Adaptimmune Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adaptimmune Therapeutics wasn't on the list.
While Adaptimmune Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
